ADT Use Not Linked to Dementia Risk in Study of Prostate Cancer Patients

ADT Use Not Linked to Dementia Risk in Study of Prostate Cancer Patients
The use of androgen deprivation therapy (ADT) in patients with prostate cancer is not associated with an increased risk of dementia, according to a recent study in the Journal of Clinical Oncology. The study, “Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer,” took issue with findings in three prior observational studies reporting a link between

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Lawrence Glickman says:

    ADT has been proven to be a temporary tool that leads in many cases to aggressive hormone resistant prostate cancer over the longer term. While all additional days of living are valuable it points up the need for better therapies. Anyone with the most basic knowledge of nutrition knows that hormones play a critical role in almost every bodily function. Suppressing all male hormones simply cannot be a good thing and in my opinion should be limited to a temporary part of more effective therapies.

    • Tim Bossie says:

      Hi Lawrence! Thank you for the comment and discussion. The need for better therapies is always something we must move forward with. However, it is good to hear some information, and news, that point to dismissing some “myths” (for lack of better word) about the therapies that are available. Having said that, though, you are right… suppressing all hormones is not a good thing. Hopefully there is a day soon when there are better alternative PC treatments.

Leave a Comment

Your email address will not be published. Required fields are marked *